Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry
- PMID: 9840434
- DOI: 10.1016/s0378-4347(98)00374-0
Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry
Abstract
A sensitive, robust and high throughput mass spectrometry based method is described for the determination of the glucocorticoid fluticasone propionate in plasma. The method employs solid-phase extraction in 96 well microtitre plate format which has been automated by means of a custom built Zymark robotic system. The extracts are analysed by liquid chromatography-tandem mass spectrometry using thermally and pneumatically assisted electrospray ionisation and selected reaction monitoring. The method is both accurate and precise with both intra- and inter-assay precision (C.V.) of less than <6%. The method provides a lower limit of quantification of 20 pg/ml from 0.5 ml of human plasma, sufficient to monitor systemic concentrations of inhaled fluticasone propionate at therapeutic doses.
Similar articles
-
An improved method for the determination of fluticasone propionate in human plasma.J Pharm Biomed Anal. 1999 Dec;21(4):749-58. doi: 10.1016/s0731-7085(99)00213-7. J Pharm Biomed Anal. 1999. PMID: 10701940
-
Quantification of epimeric budesonide and fluticasone propionate in human plasma by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry.J Chromatogr B Biomed Sci Appl. 2001 Sep 25;761(2):177-85. doi: 10.1016/s0378-4347(01)00329-2. J Chromatogr B Biomed Sci Appl. 2001. PMID: 11587347
-
A sensitive method for the quantification of fluticasone propionate in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionisation mass spectrometry.J Pharm Biomed Anal. 1997 Nov;16(3):447-52. doi: 10.1016/s0731-7085(97)00073-3. J Pharm Biomed Anal. 1997. PMID: 9589403
-
A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma.J Pharm Biomed Anal. 2000 Feb;22(1):123-9. doi: 10.1016/s0731-7085(99)00246-0. J Pharm Biomed Anal. 2000. PMID: 10727131 Clinical Trial.
-
Development of a sensitive method for simultaneous determination of fluticasone propionate and salmeterol in plasma samples by liquid chromatography-tandem mass spectrometry.Biomed Chromatogr. 2012 May;26(5):627-35. doi: 10.1002/bmc.1708. Biomed Chromatogr. 2012. PMID: 22577660
Cited by
-
Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.Eur J Clin Pharmacol. 2004 Jun;60(4):265-8. doi: 10.1007/s00228-004-0763-y. Epub 2004 Apr 28. Eur J Clin Pharmacol. 2004. PMID: 15114430 Clinical Trial.
-
Bioavailability of inhaled fluticasone propionate via chambers/masks in young children.Eur Respir J. 2012 Jan;39(1):97-103. doi: 10.1183/09031936.00185510. Epub 2011 Sep 20. Eur Respir J. 2012. PMID: 21933835 Free PMC article. Clinical Trial.
-
Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.Br J Clin Pharmacol. 2012 Jul;74(1):125-33. doi: 10.1111/j.1365-2125.2012.04222.x. Br J Clin Pharmacol. 2012. PMID: 22356350 Free PMC article. Clinical Trial.
-
Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations.Br J Clin Pharmacol. 2001 Jan;51(1):103-5. doi: 10.1046/j.1365-2125.2001.01325.x. Br J Clin Pharmacol. 2001. PMID: 11167672 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical